drugset / Trial / NCT03493061

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

NCT03493061

Phase 2 Completed 60 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis. The patients will be treated with systemic chemotherapy With irinotecan plus hepatic arterial infusion With floxuridine and oxaliplatin

Timeline

Start
2018-02-01
Primary completion
2020-12-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Floxuridine Unknown 0.12 mg/kg Other
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Dexamethasone Small molecule 25 mg Other